Two sustained-release procedural pharmaceuticals or drug-delivery options are available in the US: the bimatoprost ...
Glaucoma therapies have come a long way, but pain points still remain, according to a speaker at the American Academy of ...
Please provide your email address to receive an email when new articles are posted on . Angling a patient’s face can negate the effect of facial contour on visual field testing. AI may help predict ...
Oluwatosin U. Smith, MD, reflects on early experiences caring for pediatric patients with complex glaucoma and how evolving ...
A retrospective analysis of children diagnosed with glaucoma before the age of 3 years showed visual acuity and intraocular pressure measured 5 years after diagnosis, as well as the presence of ...
US initiative follows recent CE certification of Ciliatech’s flagship eye implant, Intercil® Uveal Spacer, novel treatment for patients with mild to moderate glaucomaDecisive move unlocks ...
Patients with newly diagnosed glaucoma who have less wealth or reside in rural communities are less likely to receive standard glaucoma care compared to wealthier patients, according to a recent multi ...
Diorasis Therapeutics, a Boston-based biotechnology company developing durable gene therapies for glaucoma and other ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback